Cannabix Technologies (CSE:BLO) (USOTC:BLOZF) has taken another step in the commercialisation of its Marijuana Breath Test (MBT), announcing a strategic move into the combat sports market through its participation at the Association of Boxing Commissions (ABC) 38th Annual Conference. The development highlights the company’s growing focus on real-world deployment in safety-critical industries where rapid, objective testing has the potential to transform decision-making.
The ABC Conference brings together athletic commissioners, regulators, medical professionals, referees and industry leaders responsible for overseeing professional boxing, mixed martial arts (MMA) and other combat sports. For Cannabix, it represents direct access to organisations actively seeking more effective methods of assessing recent cannabis use among athletes before competition, following incidents and during regulatory reviews.
Unlike traditional urine or hair testing, which can detect cannabis long after any potential effects have passed, Cannabix’s Marijuana Breath Test is designed to identify recent THC use through a fast, non-invasive breath sample. This makes the technology particularly relevant in environments where reaction time, balance, coordination and split-second decision making are essential for athlete safety. The company emphasises that the MBT is intended to detect recent use rather than determine impairment itself.
The conference appearance also reinforces Cannabix’s expanding commercial strategy. Following the phased commercial launch of the MBT earlier this year, the company has steadily targeted industries where recent-use detection provides a clear operational advantage. Workplace safety, transportation, law enforcement and now regulated sports all represent markets with growing demand for modern testing solutions as cannabis legislation continues to evolve.
An important part of this strategy is Cannabix’s collaboration with Omega Laboratories, one of North America’s leading forensic drug testing laboratories. Omega will support presentations at the conference, demonstrating how laboratory confirmation can be integrated with Cannabix’s breath collection technology to provide regulators with a practical and defensible testing workflow.
The company also sees significant long-term potential beyond cannabis detection alone. Development is already underway on a broader five-panel breath-testing platform capable of screening multiple drug classes. If successfully commercialised, this could substantially expand Cannabix’s addressable market across public safety, corrections, workplace compliance and other safety-sensitive sectors.
Chief Executive Officer Rav Mlait believes engaging directly with combat sports regulators represents an important milestone in bringing the technology closer to end users. Rather than remaining in the development phase, Cannabix is increasingly focused on demonstrating practical applications in environments where accurate, time-relevant information can support better decisions and improved safety.
For investors, the announcement demonstrates continued execution of Cannabix’s commercial roadmap. With growing industry engagement, established laboratory partnerships and a technology designed to address a long-recognised gap in cannabis testing, the company continues to build momentum as it expands into high-value markets where objective, recent-use detection could become an increasingly important component of safety and regulatory programmes.
For more information visit – https://cannabixtechnologies.com/